Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for MPDL3280A

2 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCURO14100

03/24/2015

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy

Treatment

VICCPHI1138

03/08/2012

A Phase I, Open-Label, Dose-Escalation study of the safety and Pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies